Compare · CLSD vs NVS
CLSD vs NVS
Side-by-side comparison of Clearside Biomedical Inc. (CLSD) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLSD and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 2537.3x CLSD ($112.2M).
- Over the past year, CLSD is down 96.3% and NVS is up 24.3% - NVS leads by 120.6 points.
- NVS has more recent analyst coverage (25 ratings vs 8 for CLSD).
- Company
- Clearside Biomedical Inc.
- Novartis AG
- Price
- $0.43-27.67%
- $146.67-1.61%
- Market cap
- $112.2M
- $284.62B
- 1M return
- -88.68%
- +0.87%
- 1Y return
- -96.28%
- +24.31%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 8
- 25
Clearside Biomedical Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest CLSD
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
- SEC Form POS AM filed by Clearside Biomedical Inc.
- SEC Form S-8 POS filed by Clearside Biomedical Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG